This Phase 2, multicenter, randomized, double-blind, two-way crossover trial examined the anti-tussive effects of low-dose controlled-release morphine, as compared with placebo, in 44 patients with idiopathic pulmonary fibrosis. The primary endpoint was the percent change from baseline to treatment end in daytime/awake cough frequency. Cough was objectively monitored using the Vitalograph VitaloJAK cough monitor.
- Author Wu Z et al.
- Publication The Lancet Respiratory Medicine
- Year 2024
- Device Type VitaloJAK
